Validation of a screening questionnaire for androgen deficiency in aging males.

By J. E. Morley, E. Charlton, P. Patrick, F. Kaiser, P. Cadeau, D. McCready, H. M. Perry. Metabolism: Clinical and Experimental, 2000

675 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The decline of androgen levels in elderly men and its clinical and therapeutic implications. (2005, methodology): “(410) as a screening tool for identifying middle-aged and older males with testosterone deficiency.”
Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. (2006, background): “Hypogonadism was def ined as total testosterone level!12 nmol/l (on two separate occasions) and symptoms of hypogonadism (positive ADAM score) ( 26 ).”
Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. (2006, background): “There is limited information about the performance properties of case-detection instruments that rely on self-report, namely, Androgen Deficiency in Aging Males (ADAM) (19), the Aging Males’ Symptoms (AMS) Rating Scale (20), and the Massachusetts Male Aging Study Questionnaire (21).”
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. (2010, background): “There is limited information about the performance properties of case-detection instruments that rely on selfreport, namely, Androgen Deficiency in Aging Males (41), the Aging Males’ Symptoms Rating Scale (42), and the Massachusetts Male Aging Study Questionnaire (43).”